Novel mutations and decreased expression of the epigenetic regulator TET2 in pulmonary arterial hypertension

François Potus, Michael W. Pauciulo, Elina K. Cook, Na Zhu, Alexander Hsieh, Carrie L. Welch, Yufeng Shen, Lian Tian, Patricia Lima, Jeffrey Mewburn, Christine L. D'Arsigny, Christine L. D'Arsigny, Katie A. Lutz, Anna W. Coleman, Rachel Damico, Brooke Snetsinger, Ashley Y. Martin, Paul M. Hassoun, William C. Nichols, Wendy K. ChungWendy K. Chung, Michael J. Rauh, Stephen L. Archer

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Background: Pulmonary arterial hypertension (PAH) is a lethal vasculopathy. Hereditary cases are associated with germline mutations in BMPR2 and 16 other genes; however, these mutations occur in <25% of patients with idiopathic PAH and are rare in PAH associated with connective tissue diseases. Preclinical studies suggest epigenetic dysregulation, including altered DNA methylation, promotes PAH. Somatic mutations of Tet-methylcytosine-dioxygenase-2 (TET2), a key enzyme in DNA demethylation, occur in cardiovascular disease and are associated with clonal hematopoiesis, inflammation, and adverse vascular remodeling. The role of TET2 in PAH is unknown. Methods: To test for a role of TET2, we used a cohort of 2572 cases from the PAH Biobank. Within this cohort, gene-specific rare variant association tests were performed using 1832 unrelated European patients with PAH and 7509 non-Finnish European subjects from the Genome Aggregation Database (gnomAD) as control subjects. In an independent cohort of 140 patients, we quantified TET2 expression in peripheral blood mononuclear cells. To assess causality, we investigated hemodynamic and histological evidence of PAH in hematopoietic Tet2-knockout mice. Results: We observed an increased burden of rare, predicted deleterious germline variants in TET2 in PAH patients of European ancestry (9/1832) compared with control subjects (6/7509; relative risk=6; P=0.00067). Assessing the whole cohort, 0.39% of patients (10/2572) had 12 TET2 mutations (75% predicted germline and 25% somatic). These patients had no mutations in other PAH-related genes. Patients with TET2 mutations were older (71±7 years versus 48±19 years; P<0.0001), were more unresponsive to vasodilator challenge (0/7 versus 140/1055 [13.2%]), had lower pulmonary vascular resistance (5.2±3.1 versus 10.5±7.0 Wood units; P=0.02), and had increased inflammation (including elevation of interleukin-1β). Circulating TET2 expression did not correlate with age and was decreased in >86% of PAH patients. Tet2-knockout mice spontaneously developed PAH, adverse pulmonary vascular remodeling, and inflammation, with elevated levels of cytokines, including interleukin-1β. Long-term therapy with an antibody targeting interleukin-1β blockade resulted in regression of PAH. Conclusions: PAH is the first human disease related to potential TET2 germline mutations. Inherited and acquired abnormalities of TET2 occur in 0.39% of PAH cases. Decreased TET2 expression is ubiquitous and has potential as a PAH biomarker.

Original languageEnglish (US)
Pages (from-to)1986-2000
Number of pages15
StatePublished - Jun 16 2020


  • CREST syndrome
  • Connective tissue diseases
  • DNA methylation
  • Epigenetics
  • Limited
  • Pulmonary arterial hypertension
  • Scleroderma

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Novel mutations and decreased expression of the epigenetic regulator TET2 in pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this